Urokinase

Introduction Overview

Generic Name

urokinase

Brand Name

Kinlytic, Abbokinase, Abbokinase Open-Cath

Dosage Form

intravenous powder for injection (250,000 international units)

Drug Class

Thrombolytics

Pharmacokinetics

Absorption:
Urokinase is administered intravenously, therefore it bypasses the gastrointestinal absorption processes. Following intravenous administration, urokinase enters the systemic circulation immediately, ensuring rapid onset of action. The drug is typically delivered by continuous infusion over several hours to maintain effective plasma concentrations for thrombolytic activity.

Distribution:
Upon entering the bloodstream, urokinase is distributed primarily within the vascular compartment. Due to its large molecular size as a proteolytic enzyme, it does not readily cross cellular membranes or the blood-brain barrier. The volume of distribution is limited, concentrating its effect primarily within the circulatory system. Protein binding is minimal, allowing urokinase free access to fibrin-bound plasminogen at sites of thrombosis.

Metabolism:
Urokinase, being a serine protease enzyme, is metabolized by proteolytic cleavage primarily in the liver and to some extent by plasma protease inhibitors that regulate its activity. Enzymatic degradation occurs via protease inhibitors such as alpha-2-antiplasmin, which inactivates free urokinase to prevent systemic fibrinolysis and hemorrhage. This controlled metabolism limits systemic effects and concentrates thrombolysis at clot sites.

Elimination:
Metabolic inactivation of urokinase fragments occurs predominantly in the liver, followed by renal excretion of metabolites. The plasma half-life of active urokinase is relatively short, estimated at approximately 10–20 minutes, necessitating prolonged continuous infusion for sustained thrombolytic effect. Renal clearance contributes to elimination of smaller peptide fragments. Factors affecting hepatic or renal function may influence urokinase clearance and dosing considerations.

Dosage Forms

Available Dosage Forms:
Urokinase is available as an intravenous powder for injection intended for reconstitution prior to administration. The primary dosage form is a single-dose vial containing 250,000 international units. Previously available formulations included single-dose vials of 5,000 IU and 9,000 IU, though these have been discontinued.

Dosages for Adults and Adolescents:
The standard dosing regimen for adults with acute pulmonary embolism involves an initial intravenous loading dose of 4,400 international units per kilogram infused over 10 minutes at approximately 90 mL/hr, followed by a continuous maintenance infusion at 4,400 international units per kilogram per hour at 15 mL/hr for 12 hours. Treatment should ideally commence soon after embolism onset to maximize efficacy. Dosage adjustments may be considered based on clinical response and bleeding risk.

Specific Patient Populations:
Dosing in special populations such as those with severe liver or kidney impairment is not well established and requires careful monitoring due to possible altered metabolism and elimination. Patients with recent surgery, bleeding disorders, or advanced age warrant particular caution and risk-benefit assessment prior to dosing. Pediatric dosing has not been clearly established and use in children is typically limited to specialized cases under expert supervision.

Mechanism Of Action

Urokinase is a serine protease enzyme functioning as a potent thrombolytic by directly converting plasminogen to plasmin, an enzyme responsible for fibrin clot degradation. Unlike other thrombolytics that may require fibrin binding to activate plasminogen, urokinase activates plasminogen systemically and at clot sites, initiating fibrinolysis. This process leads to the dissolution of fibrin clots obstructing blood vessels.

At the molecular level, urokinase binds to plasminogen, cleaving it to form plasmin. Plasmin then enzymatically degrades fibrin meshwork within thrombi, disrupting their structural integrity. This targeted proteolysis restores blood flow by breaking down occlusive clots in the pulmonary arteries or other vascular beds.

Furthermore, urokinase's enzymatic activity is regulated by endogenous inhibitors such as alpha-2-antiplasmin, which limits systemic fibrinolysis and reduces the risk of generalized bleeding. This balance allows for localized clot breakdown while preserving hemostasis elsewhere in the circulation.

Clinically, urokinase offers advantages in rapid clot lysis and improving hemodynamic stability in life-threatening thromboembolic conditions such as pulmonary embolism. Comparative studies show urokinase achieves effective fibrinolysis with lower antigenicity compared to other agents like streptokinase. Research supports its continued use in acute massive pulmonary embolism and other thrombotic conditions resistant to conventional anticoagulation therapies.

Pharmacological Actions

Exerts fibrinolytic activity by converting plasminogen to plasmin, leading to clot dissolution
Directly activates plasminogen without requiring fibrin binding, allowing systemic thrombolysis
Reduces vascular occlusion by lysing fibrin clots in pulmonary embolism and other thrombotic events
Restores blood flow in occluded vessels, improving tissue oxygenation and function
Regulated by endogenous protease inhibitors to minimize systemic bleeding
Degrades fibrin meshwork, disrupting thrombus structural integrity
Enhances hemodynamic stability in conditions characterized by massive thrombosis
Acts rapidly upon intravenous administration with short plasma half-life
Has lower immunogenic potential compared to streptokinase
Serves as a rescue therapy in clots refractory to anticoagulants
Potentially useful in catheter clearance by dissolving fibrin plugs
Facilitates reperfusion in ischemic tissues affected by blood clots
Minimal protein binding allows effective interaction with plasminogen
Used adjunctively with anticoagulants post-lysis to prevent re-thrombosis

Therapeutic Or Clinical Uses

Lysis of acute massive pulmonary embolism to restore pulmonary blood flow
Treatment of pulmonary embolism with hemodynamic instability or failure to maintain blood pressure
Management of thrombotic occlusions in critical vascular beds requiring urgent fibrinolysis
Adjunctive use following deep vein thrombosis to prevent embolic events
Potential use for clearing catheter occlusions caused by fibrin clots
Employed in acute thromboembolic disorders resistant to conventional anticoagulation
Used in clinical settings to improve outcomes after massive clot burden onset
Facilitates reperfusion in cases of ischemia due to obstructive clots
Selected for patients who are at risk for immunologic reactions to other thrombolytics
May be used for off-label indications involving pathological fibrin deposition
Helpful in situations where rapid restoration of vessel patency is critical
Can be combined with anticoagulants post-treatment to reduce recurrence risk
Utilized in specialized interventions such as catheter-directed thrombolysis
Considered in emergency thrombotic events when surgical thrombectomy is contraindicated

Side Or Adverse Effects

Increased risk of severe and life-threatening bleeding events, including intracranial hemorrhage
Allergic reactions presenting as hives, facial swelling, difficulty breathing
Bleeding from surgical sites, venipuncture, or injections
Gastrointestinal bleeding manifesting as bloody or tarry stools
Hematuria or bleeding from the urinary tract
Sudden neurological symptoms such as numbness, weakness, severe headache indicating possible cerebral bleeding
Signs of disseminated intravascular coagulation triggered by systemic fibrinolysis
Chest pain, back pain, or tightness potentially indicating cardiac complications
Chills, fever, nausea, light-headedness, or tachycardia shortly after administration
Swelling, rapid weight gain, or oliguria signaling potential renal complications
Skin discoloration including darkening or purplish fingers and toes
Pancreatitis characterized by severe upper abdominal pain radiating to the back
High blood pressure episodes with headache, blurred vision, anxiety, and irregular heartbeats
Muscular weakness or sudden loss of sensation in limbs indicating nervous system involvement
Potential transmission of infectious agents from plasma-derived preparation, albeit rare

Precautions

Avoid use in patients with active internal bleeding
Caution in patients with known bleeding or clotting disorders such as hemophilia
Screening for intracranial neoplasms or vascular anomalies before administration
Monitor blood pressure rigorously; uncontrolled hypertension is a contraindication
Avoid use within 2 months following stroke, brain surgery, or spinal surgery
Careful assessment if recent medical emergency requiring CPR has occurred
Monitor coagulation parameters, including activated partial thromboplastin time (aPTT), to time adjunct anticoagulation
Use cautiously in patients with severe liver or kidney impairment
Consider bleeding risk in patients with recent gastrointestinal bleeding or endocarditis
Recommend avoiding use in pregnancy unless potential benefit outweighs risk
Minimize invasive procedures during infusion to reduce hemorrhagic complications
Advise patients to avoid medications that increase bleeding risk such as NSAIDs during and shortly after treatment
Evaluate for possible immunogenic reactions, particularly if re-exposure occurs
Ensure thorough patient history regarding recent surgeries or organ transplants before administration
Ensure immediate availability of emergency medical support to manage bleeding or allergic events

Warnings

Do not use if there is active internal bleeding or bleeding disorders
Avoid in patients with brain tumors or cerebral aneurysms due to risk of hemorrhage
Risk of severe hemorrhagic complications including intracranial bleeding
Potential for serious allergic reactions requiring emergency intervention
Avoid use immediately following recent stroke, brain, or spinal surgery
Severe uncontrolled hypertension is a contraindication due to bleeding risk
Use only when benefits outweigh the risks of life-threatening bleeding
Ensure close monitoring of vital signs, oxygenation, and coagulation during therapy
Discontinue infusion immediately if severe bleeding or hypersensitivity occurs
Inform all healthcare providers if urokinase has been administered, especially in emergencies
Risk of transmission of blood-borne pathogens despite rigorous plasma screening
Avoid concomitant anticoagulant loading doses until coagulation parameters are stabilized
Risk of pancreatitis and cardiovascular complications reported during treatment
Delay anticoagulant therapy until activated partial thromboplastin time is less than twice normal
Not recommended for use without specialized medical supervision in hospital settings

Contraindication

Known hypersensitivity to urokinase or components of the formulation
Active bleeding anywhere in the body, including gastrointestinal or intracranial sites
Presence of intracranial tumor or structural brain abnormalities such as aneurysms
Severe or uncontrolled hypertension
History of hemorrhagic stroke or recent ischemic stroke within past two months
Recent brain, spinal, or major surgery within last 2 months
Bleeding disorders such as hemophilia or other coagulopathies
Recent requirement for cardiopulmonary resuscitation prior to administration
Any condition where the risk of bleeding outweighs potential benefits of thrombolysis
Pregnancy within 10 days postpartum due to increased bleeding risk
Concurrent use of other fibrinolytic agents unless clinically justified
Severe liver or renal failure without ability to monitor and manage complications
Ongoing peptic ulcer bleeding or recent gastrointestinal hemorrhage
Severe infections involving the heart valves (bacterial endocarditis)
Unstable or uncontrolled medical conditions precluding careful monitoring

Drug Interactions

Concomitant use with anticoagulants such as heparin or warfarin increases bleeding risk
Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin, ibuprofen, naproxen potentiate bleeding risk
Antiplatelet agents including clopidogrel and abciximab may have additive hemorrhagic effects
Glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban) can increase bleeding tendencies
Vorapaxar and other thrombin receptor antagonists enhance anticoagulant effects
Combination with other thrombolytics may cause excessive fibrinolysis and hemorrhage
Interaction with medications affecting coagulation pathways requires vigilant monitoring
Herbal supplements with anticoagulant or antiplatelet properties may exacerbate bleeding
Potential pharmacodynamic interaction with medications affecting platelet function
Concurrent use with corticosteroids requires cautious assessment due to bleeding risk
NSAIDs and certain analgesics should be avoided or used cautiously post-urokinase infusion
Drug interactions may alter the efficacy and safety profile necessitating adjusted dosing
Inform healthcare providers of all medications and supplements prior to urokinase treatment
Interactions primarily concern additive effects on hemostasis rather than pharmacokinetics
Careful laboratory monitoring recommended when urokinase is combined with interacting drugs

Preparations Of The Drug

Urokinase is supplied as an intravenous powder for injection, intended for reconstitution
Available primarily in single-dose vials containing 250,000 international units
Discontinued formulations include 5,000 IU and 9,000 IU single-dose vials
The drug must be reconstituted with appropriate sterile diluents prior to administration
Prepared solutions are administered via intravenous infusion using a controlled pump
Prepared dosing solutions should be used promptly to maintain enzymatic activity
Sterile technique is required during preparation and administration to prevent contamination
The medication is stored under refrigeration and protected from light until use
Preparation protocols include dosage calculations based on patient body weight
Infusion tubing and catheters must be monitored for patency and infections
Healthcare professionals must adhere to institutional guidelines for preparation and infusion
Preparation includes verification of concentration, expiration, and patient identifiers
Additional anticoagulant medications are often administered following urokinase infusion
Patient monitoring equipment should be set up concurrently during drug preparation
Disposal of unused preparation must follow biohazard protocols to prevent exposure